Xeris Biopharma announced a CEO succession plan effective August 1, under which Paul Edick will be retiring from his day-to-day operational and chairman role at Xeris after more than seven years with the company. Pursuant to the company’s succession plan, the board has appointed, John Shannon, Xeris’ president and COO, as the new CEO and a member of the board of directors. Shannon has been a member of Xeris’ executive leadership team since 2017. Edick will serve in a senior advisory role to Xeris through February 1, 2026. The company also announced that Marla Persky will be chairperson of the board effective August 1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Pharmaceuticals Shareholders Back Key Proposals and Directors
- Xeris presents data on SONICS study on effects of levoketoconazole on CS
- Xeris announces XeriSol data formulated once-weekly SC levothyroxine
- Xeris Biopharma price target lowered to $3 from $4 at Piper Sandler
- Xeris Biopharma reports Q1 EPS (14c), consensus (12c)
